425 related articles for article (PubMed ID: 21972424)
1. Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study.
Sathyapalan T; Smith KA; Coady AM; Kilpatrick ES; Atkin SL
Ann Clin Biochem; 2012 Jan; 49(Pt 1):80-5. PubMed ID: 21972424
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome.
Sathyapalan T; Shepherd J; Coady AM; Kilpatrick ES; Atkin SL
J Clin Endocrinol Metab; 2012 Nov; 97(11):3951-5. PubMed ID: 22879630
[TBL] [Abstract][Full Text] [Related]
3. Effect of atorvastatin on testosterone levels.
Shawish MI; Bagheri B; Musini VM; Adams SP; Wright JM
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013211. PubMed ID: 33482034
[TBL] [Abstract][Full Text] [Related]
4. Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome.
Kjøtrød SB; Sunde A; von Düring V; Carlsen SM
Fertil Steril; 2009 Feb; 91(2):500-8. PubMed ID: 18304542
[TBL] [Abstract][Full Text] [Related]
5. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism.
Rittmaster RS; Thompson DL
J Clin Endocrinol Metab; 1990 Apr; 70(4):1096-102. PubMed ID: 2156885
[TBL] [Abstract][Full Text] [Related]
6. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
7. Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome.
Sathyapalan T; Shepherd J; Arnett C; Coady AM; Kilpatrick ES; Atkin SL
Clin Chem; 2010 Nov; 56(11):1696-700. PubMed ID: 20817794
[TBL] [Abstract][Full Text] [Related]
8. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study.
Sathyapalan T; Kilpatrick ES; Coady AM; Atkin SL
J Clin Endocrinol Metab; 2009 Jan; 94(1):103-8. PubMed ID: 18940877
[TBL] [Abstract][Full Text] [Related]
9. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study.
Puurunen J; Piltonen T; Puukka K; Ruokonen A; Savolainen MJ; Bloigu R; Morin-Papunen L; Tapanainen JS
J Clin Endocrinol Metab; 2013 Dec; 98(12):4798-807. PubMed ID: 24152688
[TBL] [Abstract][Full Text] [Related]
10. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome.
Lerchbaum E; Schwetz V; Giuliani A; Pieber TR; Obermayer-Pietsch B
Fertil Steril; 2012 Nov; 98(5):1318-25.e1. PubMed ID: 22835450
[TBL] [Abstract][Full Text] [Related]
11. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome.
Azziz R; Ehrmann DA; Legro RS; Fereshetian AG; O'Keefe M; Ghazzi MN;
Fertil Steril; 2003 Apr; 79(4):932-7. PubMed ID: 12749433
[TBL] [Abstract][Full Text] [Related]
12. Variants in SULT2A1 affect the DHEA sulphate to DHEA ratio in patients with polycystic ovary syndrome but not the hyperandrogenic phenotype.
Louwers YV; de Jong FH; van Herwaarden NA; Stolk L; Fauser BC; Uitterlinden AG; Laven JS
J Clin Endocrinol Metab; 2013 Sep; 98(9):3848-55. PubMed ID: 23861462
[TBL] [Abstract][Full Text] [Related]
13. [Androgen and 17-hydroxyprogesterone concentrations in blood serum versus menstrual patterns in women with polycystic ovary syndrome (PCOS)].
Rudnicka E; Kunicki M; Radowicki S
Ginekol Pol; 2010 Oct; 81(10):745-9. PubMed ID: 21117302
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy of different androgens measured by LC-MS/MS in representing hyperandrogenemia and an evaluation of adrenal-origin androgens with a dexamethasone suppression test in patients with PCOS.
Chen F; Chen M; Zhang W; Yin H; Chen G; Huang Q; Yang X; Chen L; Lin C; Yin G
J Ovarian Res; 2021 Feb; 14(1):32. PubMed ID: 33583431
[TBL] [Abstract][Full Text] [Related]
15. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
[TBL] [Abstract][Full Text] [Related]
16. Impact of glycemic variations on the regulation of androgen metabolism in obese women with polycystic ovary syndrome.
Ludwig AK; Goharian LG; Dietze T; Tauchert S; Rudolf S; Diedrich K; Schweiger U; Oltmanns KM
Fertil Steril; 2009 Jul; 92(1):271-6. PubMed ID: 18692843
[TBL] [Abstract][Full Text] [Related]
17. Effects of Metformin Treatment on Soluble Leptin Receptor Levels in Women with Polycystic Ovary Syndrome.
Liu RB; Liu Y; Lv LQ; Xiao W; Gong C; Yue JX
Curr Med Sci; 2019 Aug; 39(4):609-614. PubMed ID: 31346998
[TBL] [Abstract][Full Text] [Related]
18. Cervical Length and Androgens in Pregnant Women With Polycystic Ovary Syndrome: Has Metformin Any Effect?
Shetelig Løvvik T; Stridsklev S; Carlsen SM; Salvesen Ø; Vanky E
J Clin Endocrinol Metab; 2016 Jun; 101(6):2325-31. PubMed ID: 26835542
[TBL] [Abstract][Full Text] [Related]
19. In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone.
Mazza A; Fruci B; Guzzi P; D'Orrico B; Malaguarnera R; Veltri P; Fava A; Belfiore A
Nutr Metab Cardiovasc Dis; 2014 Feb; 24(2):132-9. PubMed ID: 23845740
[TBL] [Abstract][Full Text] [Related]
20. Impact of overnight dexamethasone suppression on the adrenal androgen response to an oral glucose tolerance test in women with and without polycystic ovary syndrome.
Buyalos RP; Geffner ME; Azziz R; Judd HL
Hum Reprod; 1997 Jun; 12(6):1138-41. PubMed ID: 9221990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
